Watson and GeneraMedix announced that Nulecit, a generic of Ferrlecit (sodium ferric gluconate complex in sucrose injection; sanofi-aventis), has been approved for the treatment of iron deficiency anemia in patients ≥6 years undergoing chronic hemodialysis who are receiving supplemental epoetin therapy. Nulecit is bioequivalent and therapeutically equivalent to Ferrlecit.

Nulecit will be supplied as a 5mL glass ampule containing 62.5mg of elemental iron.

For more information call (800) 272-5525 or visit www.watson.com.